Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
36
pubmed:dateCreated
2008-9-23
pubmed:abstractText
Corticosteroids are still the first-line treatment for active ulcerative colitis more than 50 years after the publication of trials assessing their beneficial effect, with about a 50% remission rate in cases of severe disease. The mortality related to severe attacks of ulcerative colitis has decreased dramatically, to less than 1%, in experienced centers, due to the appropriate use of intensive therapeutic measures (intravenous steroids, fluids and electrolytes, artificial nutritional support, antibiotics, etc), along with timely decision-making about second-line medical therapy and early identification of patients requiring colectomy. One of the most difficult decisions in the management of severe ulcerative colitis is knowing for how long corticosteroids should be administered before deciding that a patient is a non-responder. Studies assessing the outcome of acute attacks after steroid initiation have demonstrated that, in steroid-sensitive patients, the response generally occurs early on, in the first days of treatment. Different indexes to predict treatment failure, when applied on the third day of treatment, have demonstrated a high positive predictive value for colectomy. In contrast to this resolute approach, which is the most widely accepted, other authors have suggested that in some patients a complete and prolonged response to steroids may take longer. Either way, physicians taking care of these patients need to recognize that severe ulcerative colitis may be life-threatening, and they need to be careful with excessively prolonged medical treatment and delayed surgery.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-12352296, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-13182220, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-13865152, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-14971812, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-15142197, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-15285522, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-15940615, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-16151544, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-1642220, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-16961749, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-17142106, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-3031150, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-7129207, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-7364320, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-7733078, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-82099, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-8984031, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-9011460, http://linkedlifedata.com/resource/pubmed/commentcorrection/18810766-9831403
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1007-9327
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5504-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Severe ulcerative colitis: at what point should we define resistance to steroids?
pubmed:affiliation
Department of Gastroenterology, Hospital Universitari Mutua de Terrassa, University of Barcelona, Placa Dr Robert no. 508221 Terrassa, Barcelona, Catalonia, Spain. mestevecomas@telefonica.net
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't